Identification of interleukin-6 trans-signalling as a novel target for therapeutic approaches to lung cancer

鉴定白细胞介素 6 反式信号传导作为肺癌治疗方法的新靶点

• 批准号: nhmrc : 1063998
• 负责人: Prof Brendan Jenkins
• 金额: $ 41.81万
• 依托单位: Monash University
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2014
• 资助国家: 澳大利亚
• 起止时间: 2014-01-01 至 2016-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/identification-interleukin-6-lung-cancer/455098
• 关键词: Identification; interleukin; trans; signalling; novel

Interleukin-6 (IL-6) has been implicated as a causative factor in lung cancer, the most lethal cancer worldwide, albeit by unknown mechanisms. Since IL-6 is also important for immune system homeostasis, the development of anti-IL-6 therapies requires an intimate knowledge of pathological versus physiological IL-6 signalling pathways. This project aims for the first time to define an alternative IL-6 signalling pathway, termed “trans signalling”, in the molecular pathogenesis of lung cancer.

白介素 6 (IL-6) 被认为是肺癌（全世界最致命的癌症）的致病因素，但其机制尚不清楚。由于 IL-6 对于免疫系统稳态也很重要，因此抗 IL-6 疗法的开发需要对病理性与生理性 IL-6 信号通路有深入的了解。该项目旨在首次定义肺癌分子发病机制中的另一种 IL-6 信号传导途径，称为“反式信号传导”。